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Biochemical Markers of Oxidative Stress
in Predialytic Chronic Renal Failure Patients
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Background: The present study was designed to test the hypothesis that elevated reactive oxygen species
activity and decreased antioxidant activity may contribute to the pathogenesis of chronic renal failure (CRF)
which may be aggravated by immunosuppression.
Methods: Thirty healthy controls of either sex in the age group of 25–70 years and 30 age- and sex-matched
CRF patients with serum creatinine levels > 3.0 mg/dL were included in the study. Serum malondialdehyde
(MDA), adenosine deaminase (ADA), ferric reducing antioxidant power (FRAP), blood urea nitrogen, and
creatinine were estimated.
Results: There were statistically significant decreases in predialysis serum ADA and FRAP, and a statistically
significant increase in MDA levels in CRF patients compared to controls. MDA showed significant positive
correlation with serum creatinine (r = 0.79, p < 0.01). FRAP showed nonsignificant negative correlation with
serum creatinine (r = –0.02, p > 0.05). Significant negative correlation was observed between MDA and FRAP
(r = –0.55, p < 0.01) in CRF patients. Nonsignificant negative correlation was observed between ADA and
MDA (r = –0.0087, p > 0.05), and nonsignificant positive correlation was observed between ADA and FRAP
(r = 0.315, p > 0.05) in CRF patients.
Conclusion: These results are suggestive of oxidative stress leading to progressive renal injury along with
immunosuppression. FRAP can be a useful indicator to monitor and optimize antioxidant therapy, which may
potentially become an important adjunct in the management of CRF patients. [Hong Kong J Nephrol 2008;10
(2):69–73]
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INTRODUCTION
Adenosine deaminase (ADA), found in large amounts
particularly in mononuclear cells, is a marker of T-cell
activation and is related to the production of reactive
oxygen species (ROS) by neutrophils. A normal ADA
activity level prevents adenosine accumulation and thus
ensures normal lymphocyte development and function.
Chronic renal failure (CRF) may lead to a defect in the
cellular arm of the immune response and depress ADA
activity. Cell death caused by the accumulation of
extracellular adenosine is believed to contribute to the
profound loss of T lymphocytes in patients with ADA
deficiency. Adenosine-induced apoptosis is associated
with the generation of ROS and a reduction in
mitochondrial transmembrane potential. Decreased ADA
and increased malondialdehyde (MDA) production due
to increased neutrophil-derived ROS production might
suggest the presence of an interrelationship between T
cells and neutrophils in such patients [1,2]. Free radical-
induced lipid peroxidative tissue damage has been
implicated in the pathogenesis of CRF. To circumvent
the damage caused by free radicals, a variety of
enzymatic and nonenzymatic antioxidants are present
in human serum. Oxidative stress results from the
imbalance between oxidative and antioxidative
mechanisms with increased levels of pro-oxidants and
depletion of antioxidants leading to tissue damage [3].
No single component of serum antioxidant complex
could fully reflect the protective efficiency of blood,
probably because of interactions that occur in vivo
among different antioxidant compounds. Total
antioxidant capacity considers the cumulative effect of
all antioxidants present in blood and body fluids [4].
There are conflicting and inconsistent data reported on
ADA values and oxidative stress in CRF patients [5,6].
The present study was designed to test the hypothesis
that elevated ROS activity and decreased antioxidant
activity may contribute to the pathogenesis of CRF which
may be aggravated by immunosuppression. Serum
creatinine, blood urea nitrogen (BUN) and ADA were
measured in healthy controls and cases and correlated
with serum MDA and ferric reducing antioxidant power
(FRAP, which is a measure of total antioxidant capacity).
MDA is an indicator of lipid peroxidation while ADA is
an indicator of immunity. Total antioxidant capacity may
be useful as an indicator of antioxidant defence and in
monitoring antioxidant therapy.
METHODS
This study was conducted at M.S. Ramaiah Medical
Teaching Hospital in Bangalore and included 30 healthy
controls of either sex aged 25–70 years and 30 age-
and sex-matched patients who were clinically diagnosed
with CRF (on conservative management before
dialysis) due to chronic glomerulonephritis or other
glomerular diseases, chronic pyelonephritis or
obstructive uropathy with serum creatinine > 3.0 mg/
dL. Patients with CRF due to diabetes mellitus, liver
disease, coronary artery disease, vasculitis, lupus
glomerulonephritis or other autoimmune disorders were
excluded. This study was approved by the institution’s
ethics committee, and informed consent was obtained
from every subject.
Under aseptic conditions, 5-mL samples of fasting
blood were collected in plain vacutainers. Clotted blood
was centrifuged. The clear serum was separated and
used for the measurement of creatinine, BUN, ADA,
MDA and FRAP levels. All the chemicals used were
of the highest analytical grade available in India.
Serum creatinine and BUN were estimated by
standard clinical chemistry methods [7]. Total
antioxidant capacity was measured by FRAP assay
according to the method of Benzie and Strain [8]. At
low pH, when ferric tripyridyltriazine (Fe III-TPTZ)
complex is reduced to the ferrous (Fe II) form, an
intense blue color with an absorption maximum at 593
nm develops.
Lipid peroxidation was measured by serum MDA
estimation according to the colorimetric method of
Satoh [9]. Lipoproteins are precipitated from the
specimen by adding trichloroacetic acid. Then, 0.05 M
sulfuric acid and 0.67% thiobarbituric acid (TBA) in 2
M sodium sulfate are added to this precipitate and the
coupling of lipid peroxide with TBA is carried out by
heating in a boiling water bath for 30 minutes. The
resulting chromogen is extracted in n-butanol, which
is measured colorimetrically at 530 nm.
ADA activity was determined by the colorimetric
method [10,11] based on the hydrolytic activity of ADA
on adenosine, the ammonia formed being measured by
the Berthelot reaction. Adenosine 0.675 mM was used as
a substrate in 0.2 M phosphate buffer at a pH of 7.05.
After incubation at 37°C for 1 hour, the ammonia
liberated was estimated by measuring the blue color
produced with the phenol–hypochlorite reagent at 640 nm.
Statistical analysis was performed with Student’s t
test and Pearson’s correlation coefficient using SPSS
version 16.0 (SPSS Inc., Chicago, IL, USA). A value
of p < 0.05 was taken to indicate statistical significance.
RESULTS
The control group consisted of 16 males and 14 females,
and the CRF group also had 16 males and 14 females.
Distribution by age were: 8 controls and 8 cases aged
25–35 years; 6 controls and 6 cases aged 35–45 years;
10 controls and 10 cases aged 45–55 years; and 6
controls and 6 cases aged *55 years.
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Significantly decreased FRAP and ADA levels, and
significantly increased MDA level were found in the
CRF group compared to the control group (all p < 0.01;
Table 1). There was a significant positive correlation
between MDA and FRAP in the control subjects (r =
0.52, p < 0.01; Figure 1). In CRF patients, there was a
significant positive correlation between creatinine and
MDA (r = 0.79, p < 0.01), and significant negative
correlations between BUN and FRAP (r = –0.39,
p < 0.01) and between MDA and FRAP (r = –0.55,
p < 0.01) (Table 2; Figure 2). There were nonsignificant
negative correlations between creatinine and FRAP
(r = –0.02, p > 0.05), between ADA and creatinine
(r = –0.11, p > 0.05), and between ADA and MDA
(r = –0.0087, p > 0.05) (Table 2). There were
nonsignificant positive correlations between BUN and
MDA (r = 0.00059, p > 0.05) and between ADA and
FRAP (r = 0.315, p > 0.05) in CRF patients (Table 2).
DISCUSSION
ADA, an enzyme of purine catabolism, catalyzes the
conversion of adenosine to inosine and deoxyadenosine
to deoxyinosine and helps in the maturation and
function of T lymphocytes via noncovalent binding to
the T-cell antigen CD26. CRF may lead to a defect in
the cellular arm of the immune response. Some studies
have demonstrated low predialytic ADA levels in CRF
patients while some suggest normal ADA activity levels.
Uremic toxins depress ADA activity which results from
the deactivation of lymphocytes. Low ADA activity will
lead to increased adenosine (a local hormone, produced
by mesangial cells) levels, decreasing glomerular
fil tration rate,  exerting immunosuppressive,
antiproliferative and anti-inflammatory properties [1].
Depressed ADA activity with increased MDA
production suggests increased neutrophil-derived ROS
production. ROS cause tissue damage by denaturing
or modifying lipids, proteins, carbohydrates, DNA and
other molecules. Under normal conditions, ROS
produced in the course of metabolism are contained by
the body’s natural antioxidant system that consists of a
series of antioxidant enzymes such as superoxide
dismutase, catalase, glutathione peroxidase as well as
numerous endogenous and dietary antioxidant
compounds that are capable of reacting with and
inactivating ROS, thereby protecting functional and
structural molecules against ROS-mediated tissue
damage [2–4]. Evidence of renal damage mediated by
oxidative stress causing glomerular, tubulointerstitial
and endothelial alterations have been reported,
suggesting that CRF is a pro-oxidant state and that the
degree of intracellular and extracellular oxidative stress
Table 1. Comparison of measured parameters in healthy controls and chronic renal failure (CRF) patients
Controls (n = 30) CRF patients (n = 30) p
MDA (nmol/mL) 0.88 ± 0.164 2.65 ± 0.632 < 0.01
FRAP (+mol/mL) 1,018.67 ± 125.64 699.33 ± 135.5 < 0.01
ADA (U/L) 25.01 ± 5.04 18.03 ± 3.02 < 0.01
Serum Cr (mg/dL) 0.72 ± 0.107 5.32 ± 1.54 < 0.01
BUN (mg/dL) 11 ± 3.42 53.02 ± 19.96 < 0.01
MDA = malondialdehyde; FRAP = ferric reducing antioxidant power; ADA = adenosine deaminase; Cr = creatinine; BUN = blood urea
nitrogen.
Table 2. Correlation between measured parameters in chronic renal failure patients
r p
Correlation between
Serum Cr and MDA 0.79 < 0.01
Serum Cr and FRAP –0.02 > 0.05
Serum Cr and ADA –0.11 > 0.05
MDA and FRAP –0.55 < 0.01
BUN and MDA 0.00059 > 0.05
BUN and FRAP –0.39 < 0.01
ADA and MDA –0.0087 > 0.05
ADA and FRAP 0.315 > 0.05
Cr = creatinine; MDA = malondialdehyde; FRAP = ferric reducing antioxidant power; ADA = adenosine deaminase; BUN = blood urea
nitrogen.
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is related to the severity of renal failure [5,6]. MDA is
a three carbon, low molecular weight aldehyde that can
be produced from free radical attack on polyunsaturated
fatty acids of biological membranes. The determination
of MDA is used for monitoring lipid peroxidation in
biological samples [12,13]. FRAP assay is presented
as a novel method of assessing total antioxidant capacity
and is considered to be a useful indicator of the system’s
ability to regulate damage due to ROS [14]. Studies of
total antioxidant capacity in CRF patients have shown
varying results [15]. Several studies suggest that there
is enhancement of lipid peroxidation and decrease of
antioxidant defense in the course of CRF progression,
which could promote oxidative damage in the kidneys
even before the initiation of dialysis and renal
replacement therapy [16–18]. The precise mechanism
(s) of CRF-induced oxidative stress has not been
elucidated. Upregulation of NADPH oxidase abundance
or activity and imbalances in the intracellular redox
systems impairing detoxification mechanisms can lead
to oxidative stress [19].
In the present study, the significantly decreased
predialysis serum ADA concentration in CRF patients
compared to controls suggests depressed cellular
immunity in CRF. The significantly elevated predialysis
serum MDA concentration in CRF patients compared
to controls reflects the increased formation of ROS and
lipid peroxidation with progressive renal failure. The
significantly lower serum FRAP concentration in CRF
patients compared to controls reflects a lower total
antioxidant capacity. The positive correlation between
ADA and FRAP, and the negative correlations between
ADA and creatinine and between ADA and MDA
suggest a degree of immunosuppression which may also
play a role in oxidative stress in CRF.
From these results, increased oxidative stress in CRF
patients along with immunosuppression can most likely
be concluded. These markers can be useful to monitor
and optimize antioxidant therapy which may be an
important adjunct in the management of patients with
CRF.
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